We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Androgendeprivationstherapie und kardiovaskuläre Morbidität beim Prostatakarzinom: ein narratives Review.
- Authors
Klemm, Jakob; von Deimling, Markus; Fisch, Margit; Kramer, Gero; Tilki, Derya; Steuber, Thomas; von Amsberg, Gunhild; Hengstenberg, Christian; Shariat, Shahrokh F.
- Abstract
Prostate cancer is the most common malignancy in men, mostly affecting older men who harbor an increased prevalence of cardiovascular disease and metabolic syndrome. Androgen deprivation therapy (ADT), the standard therapy for various stages of prostate cancer, further increases the risk for cardiovascular disease and for metabolic syndrome. Therefore, screening for cardiovascular risk factors should be performed prior to the initiation of ADT, and, if necessary, cardiological evaluation and interdisciplinary management should be provided during and after completion of ADT. Moreover, the use of a gonadotropin-releasing hormone (GnRH) antagonist may help reduce cardiovascular risk in patients with cardiovascular disease.
- Subjects
ANTIANDROGENS; CARDIOVASCULAR diseases; CARDIOVASCULAR diseases risk factors; PROSTATE tumors; DISEASES; HORMONE therapy; GONADOTROPIN releasing hormone; METABOLIC syndrome
- Publication
Die Urologie, 2024, Vol 63, Issue 3, p262
- ISSN
2731-7064
- Publication type
Article
- DOI
10.1007/s00120-023-02222-1